BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 14, 2016
View Archived Issues
Enanta Pharmaceuticals patents FXR agonists
Read More
Merck & Co. discloses OX2 receptor antagonists
Read More
Sage Therapeutics describes GABA receptor modulators
Read More
Eleven Biotherapeutics submits IND for EBI-031, licenses IL-6 technology to Roche
Read More
First-in-human data for MGD-010
Read More
Wanbang Biopharmaceuticals to prepare IND application for SBM-TFC-039
Read More
FDA will review biosimilar application for Amgen's adalimumab
Read More
Biosimilar rituximab GP-2013 shows bioequivalence
Read More
Clinical trial data delineate activity of pembrolizumab in advanced sarcoma and thyroid cancer
Read More
GS-9876: preclinical data
Read More
Teva voluntarily suspends sales of Zecuity following adverse application site reactions
Read More
Eisai presents latest phase I/II data for E-6011 in rheumatoid arthritis and Crohn's disease
Read More
High rate of response seen with SL-401 in blastic plasmacytoid dendritic cell neoplasm
Read More
Fibrocell Science starts recruiting patients in study of FCX-007
Read More
Revance discontinues development of RT-001 for lateral canthal lines on basis of phase III results
Read More
Symic Biomedical reports treatment of first patient with SB-061
Read More
Ra Pharmaceuticals discloses phase I results for RA-101495
Read More
FDA issues complete response letter for Apadaz
Read More
Adamas Pharmaceuticals reports positive results in phase II trial for amantadine
Read More
Marinus Pharmaceuticals announces topline results from phase III trial of ganaxolone
Read More
Otsuka Pharmaceutical terminates emixustat and OPA-6566 agreements with Acucela
Read More
FDA grants fast track designation to ProMetic's IV plasminogen
Read More
ContraVir Pharmaceuticals/Ciclofilin Pharmaceuticals merger complete
Read More
FDA accepts NDA for CL-108 for review
Read More
FDA grants breakthrough therapy designations to Shire's SHP-621 and SHP-625
Read More
BioSpecifics Technologies reports positive results on CCH phase II trial
Read More
Surface BST2 shows promise as a biomarker for interferon response in patients with SLE
Read More
Tyme Technologies begins recruiting for phase Ib/II trial of SM-88
Read More